[1].Wen PY, Macdonald DR, Reardon DA, et al. Updated responseassessment criteria for high-grade gliomas: response assessment inneuro-oncology working group. J Clin Oncol 2010;28:1963-1972.
[2].Brandes AA, Tosoni A, Franceschi E, et al. Recurrencepattern after temozolomide concomitant with and adjuvant to radiotherapy innewly diagnosed patients with glioblastoma: correlation With MGMT promotermethylation status. J Clin Oncol 2009;27:1275-1279.
[3].Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PETimaging of brain tumors: comparison study with 18F-FDG PET and evaluation ofdiagnostic accuracy. J Nucl Med 2006;47:904-911.
[4].Herrmann K, Czernin J, Cloughesy T, et al. Comparison ofvisual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrencedetection in glioblastoma patients. Neuro-oncology 2014;16:603-609.
[5].Walter F, CloughesyT, Walter MA, et al. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalaninePET/CT on managing patients with brain tumors: the referring physician'sperspective. J Nucl Med 2012;53:393-398.
[6].Albert NL, Weller M, Suchorska B, et al. Response Assessmentin Neuro-Oncology working group and European Association for Neuro-Oncologyrecommendations for the clinical use of PET imaging in gliomas. Neuro-oncology2016;18:1199-1208.
[7].Voges J, Herholz K, Holzer T, et al. 11C-methionine and18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis ofcerebral glioma and monitoring after brachytherapy with 125I seeds. StereotactFunct Neurosurg 1997;69:129-135.
[8].Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responsesin temozolomide treated low-grade glioma patients. Journal of neuro-oncology2009;95:87-93.
